|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
ParaPro Pharmacuticals |
|---|---|
| Information provided by: | ParaPro Pharmacuticals |
| ClinicalTrials.gov Identifier: | NCT00545753 |
Purpose
A comparative safety and efficacy study of NatrOVA Creme Rinse - 1% versus NIX Creme Rinse, under actual use conditions in subjects 6 months of age or greater who are infested with Pediculosis capitis (human head lice).
| Condition | Intervention | Phase |
|---|---|---|
|
Pediculosis Capitis(Head Lice) |
Drug: Spinosad Creme Rinse Drug: Permethrin 1% |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Phase 3 Comparative Safety and Efficacy Study Between NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects >6 Months of Age or Older With Pediculosis Capitis |
| Estimated Enrollment: | 510 |
| Study Start Date: | September 2007 |
| Study Completion Date: | May 2008 |
| Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
A: Experimental
NatrOVA Creme Rinse - 1% - no nit combing required
|
Drug: Spinosad Creme Rinse
10 minute topical application product, following by a complete rinse off.
|
|
B: Experimental
NatrOVA Creme Rinse - 1% - nit comb regimen required
|
Drug: Spinosad Creme Rinse
10 minute topical application followed by a complete rinse off, followed by a nit combing regimen
|
|
C: Active Comparator
NIX Creme Rinse applied to OTC Instructions for Use
|
Drug: Permethrin 1%
Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
|
This is a Phase 3 multi-site, randomized, evaluator/investigator-blinded, three-arm, parallel group study evaluating the safety and efficacy of NatrOVA Creme Rinse - 1% (with nit combing and without nit combing) versus NIX Creme Rinse in an "actual use" environment.
Eligibility| Ages Eligible for Study: | 6 Months and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Females who are pregnant or nursing. Females of childbearing potential must have a negative urine pregnancy test prior to treatment at Day 0.
If a household has a pregnant female with an active case of head lice, the entire household is excluded from participation. If the pregnant household member does not have lice, this individual must NOT be the caregiver (one who provides treatment to other household members).
Contacts and Locations| United States, Arizona | |
| Hill Top Research | |
| Scottsdale, Arizona, United States, 85251 | |
| United States, Arkansas | |
| Burke Pharmaceutical Research | |
| Hot Springs, Arkansas, United States, 71913 | |
| United States, California | |
| Impact Clinical Trials | |
| Beverly Hills, California, United States, 90211 | |
| United States, Florida | |
| DMI Healthcare Group | |
| Largo, Florida, United States, 33773 | |
| United States, Ohio | |
| Haber Dermatology & Cosmetic Surgery | |
| South Euclid, Ohio, United States, 44118 | |
| Hill Top Research | |
| Miamiville, Ohio, United States, 45147 | |
| Study Director: | Bill Miller, MD | Concentrics Research |
More Information
| Responsible Party: | ParaPRO, LLC ( William Culpepper, III ) |
| Study ID Numbers: | SPN-301-07 |
| Study First Received: | October 15, 2007 |
| Last Updated: | May 16, 2008 |
| ClinicalTrials.gov Identifier: | NCT00545753 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Human Head lice |
|
Lice Infestations Skin Diseases, Infectious Skin Diseases Permethrin Parasitic Diseases |
|
Lice Infestations Ectoparasitic Infestations Skin Diseases, Infectious Molecular Mechanisms of Pharmacological Action Skin Diseases |
Skin Diseases, Parasitic Permethrin Enzyme Inhibitors Parasitic Diseases Pharmacologic Actions |